GFM
TNGX icon

GF Fund Management’s Tango Therapeutics TNGX Stock Holding History

GF Fund Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89.2K Sell
2,852
-159
-5% -$3.93K ﹤0.01% 344
2026
Q1 		$63K Buy
3,011
+365
+14% +$5.08K ﹤0.01% 378
2025
Q4 		$23.4K Buy
2,646
+252
+11% +$2.17K ﹤0.01% 489
2025
Q3 		$20.1K Sell
2,394
-271
-10% -$1.83K ﹤0.01% 485
2025
Q2 		$13.6K Hold
2,665
– – ﹤0.01% 537
2025
Q1 		$3.65K Buy
2,665
+410
+18% +$1.01K ﹤0.01% 635
2024
Q4 		$6.97K Buy
+2,255
New +$10.5K ﹤0.01% 589

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

GF Fund Management's TNGX Position: Q2 2026 in Review

GF Fund Management reduced its Tango Therapeutics (TNGX) stake by 5.3% in Q2 2026, selling an estimated $3.93K and leaving 2,852 shares worth $89.2K. The position accounts for ﹤0.01% of the portfolio, ranked #344.

GF Fund Management first reported a position in TNGX in Q4 2024 and has held it in 7 quarters since. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • GF Fund Management held 2,852 shares of Tango Therapeutics worth $89.2K as of Q2 2026.
  • GF Fund Management sold 159 Tango Therapeutics shares in Q2 2026, an estimated $3.93K.
  • Tango Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #344 holding.
  • GF Fund Management first reported a position in Tango Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.